期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021; 10 (8)
To assess the bioequivalence of 2 formulations of aripiprazole orally disintegrating tablets and to monitor their safety and tolerability in Chinese s......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021; 10 (9)
Pamiparib, a selective poly (ADP-ribose) polymerase 1/2 inhibitor, demonstrated tolerability and antitumor activity in patients with solid tumors at 6......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, ; ()
Dapoxetine is the first oral medication specifically developed for the on-demand treatment of premature ejaculation. The pharmacokinetics and safety o......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, ; ()
The purpose of this study was to determine whether the reference formulation and test formulation of acarbose are bioequivalent among healthy Chinese ......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, ; ()
This study investigated the pharmacokinetics, pharmacodynamics, and safety of fotagliptin benzoate (fotagliptin), a dipeptidyl peptidase-4 (DPP-4) inh......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, ; ()
The present study assessed the pharmacokinetics and bioequivalence of a single 10-mg dose of a generic and the branded formulation (Ocaliva) of obetic......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, ; ()
Multiple-dose pharmacokinetics (PK) and safety were investigated in this phase 1 study of PF-06372865, a positive allosteric modulator of alpha 2/3/5 ......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021; 10 (4)
This study assessed whether the reference and test formulations of dapoxetine hydrochloride were bioequivalent under fed and fasting conditions postad......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021; 10 (3)
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We characterized tofacitinib pharmacokinet......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020; 9 (8)
In patients with coronary heart disease undergoing primary prevention, hypertriglyceridemia is a residual risk for cardiovascular events. Omega-3 carb......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020; 9 (8)
The objective of this phase 1 study was to evaluate the pharmacokinetics, safety, and tolerability of baricitinib after single and multiple doses in h......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020; 9 (1)
Ertugliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, prevents renal glucose reabsorption resulting......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020; 9 (1)
A fixed-dose combination (FDC) of ertugliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and immediate-release metformin is approved for......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020; 9 (7)
Tafamidis, a non-nonsteroidal anti-inflammatory benzoxazole derivative, acts as a transthyretin (TTR) stabilizer to slow progression of TTR amyloidosi......
期刊： CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020; 9 (5)
Sildenafil citrate is approved to treat erectile dysfunction. An orally disintegrating tablet (ODT) of sildenafil citrate that does not require swallo......
